key: cord-0953905-gs81pnii
authors: Azhar, Asim; Khan, Wajihul Hasan; Khan, Parvez Anwar; Al-hosaini, Khaled; Owais, Mohammad; Ahmad, Aijaz
title: Mucormycosis and COVID-19 pandemic: Clinical and diagnostic approach
date: 2022-02-18
journal: J Infect Public Health
DOI: 10.1016/j.jiph.2022.02.007
sha: 2e24acfa11fae92f47c403c998b6428bab1b0129
doc_id: 953905
cord_uid: gs81pnii

The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is yet to be controlled worldwide, especially in India. The second wave of coronavirus disease 2019 (COVID-19) led to panic and confusion in India, owing to the overwhelming number of the population that fell prey to this highly infectious virus of recent times. In the second wave of COVID-19, the patients had to fight both the virus and opportunistic infections triggered by fungi and bacteria. Repeated use of steroids, antibiotics, and oxygen masks during the management of severely and critically ill COVID-19 patients nurtured opportunistic infections such as mucormycosis. Despite mucormycosis being a decades-old disease, it has gained notice of its widespread occurrence in COVID-19 patients throughout India. Instances of mucormycosis are usually unearthed in immunocompromised individuals and are caused by the inhalation of filamentous fungi, either from the natural environment or through supportive care units. In the recent outbreak during the second wave of COVID-19 in India, it has been seen to cause secondary infection as it grows along with the treatment of COVID-19. Furthermore, COVID-19 patients with comorbidities such as diabetes were more likely to have the mucormycosis co-infection because of their challenged immune systems’ inability to fight it. Despite the hype, mucormycosis still remains neglected and least studied, which is predominantly due to all focus on diagnostics, vaccine, and therapeutic research. In this review, we emphasize mainly on the association of mucormycosis in COVID-19 patients. We also present the molecular mechanism of mucormycosis for a better understanding of the fungal infections in patients who have recently been infected with SARS-CoV-2. Better understanding of fungal pathogens, immediate diagnosis, and management of the infections are crucial in COVID-19 patients, as high mortalities have been recorded in co-infected patients despite recovery from COVID-19.

including nausea, vomiting, diarrhea, and abdominal pain [12] . Initially, COVID-19 were perceived as flu (influenza) due to their overlapping sign and symptoms. The distinction between these two highly contagious respiratory illnesses is based on proper testing to confirm a diagnosis.

COVID-19 has been linked with a gamut of opportunistic fungal and bacterial infections, which develop once the highly infectious virus destroys the patients' natural immunity [1] . In India, numerous cases of mucormycosis were reported during the recovery from COVID-19 of patients with a previous history of diabetes or exhibiting other comorbidities. In a recent report of 275 CAM cases, 233 of which were reported from India and 42 from the rest of the world, which indicate diabetes mellitus was the most frequent underlying risk factor for CAM in India compared to other nations [13] . In another investigation on 99 CAM patients, it was found that most incidences (72%) were reported in India, and most of the patients (78%) were males with diabetes mellitus (85%). A history of COVID-19 was found in 37% of individuals who had mucormycosis after an initial recovery [14] . Mucormycosis mortality was at 50% before the COVID-19 pandemic. However, during the current pandemic in India, it has risen to 85% [15] . The incidence of CAM was 50 times higher (seven instances per 1000 patients) than the highest known background of mucormycosis cases (0.14 cases per 1000 patients), according to a meta-analysis of 52,916 COVID-19 patients [16] . A case-control analysis of 352 patients (152 cases and 200 controls) found that diabetes, systemic steroids, extended use of cloth and surgical masks, and frequent nasopharyngeal swab testing were all linked to an elevated risk of CAM [17] . SARS-CoV-2 infected patients typically show a low level of oxygen, high blood glucose (diabetes), and immunocompromised system to fight the disease (SARS-CoV-2 mediated or steroid-induced) [18] .

In this article, we detailed mucormycosis and summarized its association with SARS-CoV-2.

During COVID-19, intermittent use of steroids, supportive oxygen from cylinders, and ventilators (in critically ill patients) have played a crucial role in patients' acquisition of a J o u r n a l P r e -p r o o f secondary opportunistic infection such as mucormycosis, also known as a black fungus.

Mucormycosis is an angioinvasive severe fungal infection which spreads very fast to other parts of the body. If not diagnosed and managed within a stipulated time, mucormycosis can have serious repercussions and lethal to the affected patients.

For this article, we searched and reviewed publications on COVID-19 and mucormycosis.

PubMed, ScienceDirect and Scopus were searched for research articles written on in English using the search words COVID-19/Pandemic, SARS-CoV-2, Mucormycosis, the second wave of coronavirus disease/mucormycosis, and coronavirus. The search was done in duplicate by two different individuals for the reproducibility with exclusion criteria for non-English articles and non-COVID-19 papers. Reports and updates from the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), and from other authentic sources were added. The results were grouped and systematically presented in this review.

Mucormycosis has a long history dating back to 1885, when Palatuf described this as phacomycosis or zygomycosis [19] . The term mucormycosis was later coined by Baker in 1957 [20] . Mucormycosis is a rare but possibly fatal fungal infection triggered by a group of molds collectively called mucormycetes. The mold fungi belong to Rhizopus, Mucor, Rhizomucor, Cunninghamella, and Absidia [21] . Mucormycosis is a severe and deadly fungal infection by causative organisms belonging to the subphylum mucoromycotina and the order in Mucorales [22] . Mucorales are widely available in nature, including in soil, decaying vegetable matter, bread, and dust. The infection of mucormycosis occurs due to the inhalation of spores containing Mucorales from the intake of contaminated food materials or through damaged skin and wounds [23] . In both developing and developed nations, mucormycosis is J o u r n a l P r e -p r o o f mainly found in the immunocompromised hosts. It is generally found in patients with uncontrolled diabetes, influenza, SARS-CoV-2, and poor hygiene conditions, and in persons who have suffered from severe trauma [24] . Mucormycosis is primarily caused by the invasion of blood vessels, which leads to thrombosis, necrosis infraction of tissue, and death.

Generally, the global incidences of mucormycosis varies in the range of 0.003 -0.005 to 1.7 million of the population; however, in 2019 -2020, the incidence of prevalence became 80 times higher in India than any other nation [24] [25] [26] [28] . Table 1 is the simple and updated presentation of the previously published data by Singh AK et al., [29] . The increasing figures of mucormycosis cases associated with COVID- 19 have become the primary cause of concern, with an elevated overall mortality rate of more than 45% [30] . Mucormycosis, if diagnosed at a right time can be controlled; however, if not treated at the right time, mucormycosis can affect organs such as the eyes, upper part of the nasal cavity, and brain. In these cases, the patient needs immediate surgical intervention to stop other vital organs from dangerous infections. As mucormycosis is an opportunistic infection, it is often misidentified and therefore, resulting in poor prognosis of the disease [70] . In low-and middle-income countries including India, diagnoses of mucormycosis-causing pathogens are often identified by phenotypic characteristics such as growth rate, colony morphology, and reproductive structures [71] . In our laboratory, culturing and routine microscopy was used to J o u r n a l P r e -p r o o f identify the different forms of mucors from the biopsy, aspirate, and autopsy specimens ( Figure 1 ).

The signs and symptoms of mucormycosis are swelling of the face, fever, headache, nasal or sinus congestion, black scratch on the nose or upper inside of the mouth. Mucormycosis affects different body parts such as the sinuses, brain, and lungs [72] . Based on an anatomical site, mucormycosis infection is categorized into six types, namely (i) rhino-orbital cerebral mucormycosis (ROCM), (ii) pulmonary (iii) cutaneous (iv) gastrointestinal (v) disseminated, and (vi) miscellaneous forms.

ROCM is the most common type of mucormycosis seen in immunocompromised patients exhibiting uncontrolled diabetes mellitus (particularly with acidosis and ketoacidosis), hematologic dyscrasias, retroviral disease, steroid therapy, and malnourishment [69, 73] .

Cases of ROCM are also reported in patients undergoing deferoxamine therapy, overload of iron, and in some cases of drug abuse.

The most common pathophysiology of ROCM is high blood sugar, where Rhizopus grows efficiently. In a retrospective study on six COVID-19 patients who had ROCM, all of the patients were men, with a mean blood glucose level of 222.5 ± 144.4 (86-404) mg/dL except for one patient who had mucormycosis at the same time as COVID-19 [29] . A study describes the instance of a patient with COVID-19 infection who developed rhino-orbital mucormycosis following therapy [24] . The fungus utilizes its ketone reductase system to survive in the acidic environment of DKA. Acidosis helps in the dissociation of iron, thereby sequestering proteins in the serum, which encourage virulence and survival of the fungus.

Deferoxamine causes iron-richness, which acts as an iron-chelating agent, favoring fungal propagation by serving as siderophores to the fungus for its propagation [74] .

The fungus exhibits the ability to damage the internal lamina of blood vessels, particularly the arteries, lymphatics, and veins by toxic and mechanical means. Once spores enter sinuses, the angioinvasive infection starts germinating into manifold hyphae in the immunocompromised patients. It is believed that the pterygopalatine fossa is the largest reservoir of the fungal hyphae [75] . In the next few hours, the fungus spreads and invaginates Magnetic resonance imaging and computed tomography scans of the affected regions such as the paranasal sinus, the bones of the nasal, the septa, the orbit maxilla, and the mandible can assist detection. The radiodiagnosis techniques can examine any destruction of bones in nasal septa; osseous erosion, mucosal thickening, hypo/mild/hyper sinusitis, orbital cellulitis, soft tissue infiltration in the optical apex, optic neuritis, bone rarefaction and erosion of the skull base, infracts, and intracranial abscesses in the brain [76, 77] .

Many fungal infection cases are reported nowadays in COVID-19 hosts, including candidiasis and pulmonary aspergillosis. There are several mechanisms by which mucormycosis affects COVID-19 patients. In COVID-19 infection, there is a high impact on the immune system through inflammation, an increase in the number of neutrophil cells, a decrease in the number of lymphocyte cells, and mainly by its effect on CD4 + and CD8 + T cells. In SARS-CoV-2 infection, the number of neutrophils increases. CD4 + and CD8 + T cells play an essential role in mucormycosis infection in COVID-19 hosts through IL-4, IL-10, IL- 17, and interferon-γ (IFN-γ) [78] .

Coronavirus infection with mucormycosis has a high mortality rate owing to complications such as cavernous sinus thrombosis, disseminated infection, and osteomyelitis. Diagnosis of mucormycosis is involved in routine blood check-ups, biopsy, and radio imaging. The standard treatment for mucormycosis is first to reduce risk factors, remove the damaged tissue or organ by surgical procedure, and use intravenous anti-fungal drugs such as liposomal Amphotericin B (L-AmB) [79] .

Historically, the first case of pulmonary mucormycosis was explained in 1876 by Furbringer [80] . In 1971, Baker comprehensively illustrated most of the results of mucormycosis hitherto described [20] . 

Cutaneous mucormycosis is a rare fungal infection caused by an opportunistic fungus of the Underlying immunosuppression must be treated for appropriate fungal infection care and better survival chances, and a combination of intensive surgical therapy and antifungal medication should be explored.

Patients with COVID-19 may be more prone to fungal infections. Mucormycosis of the gastrointestinal (GI) system is caused by ingestion of fungus spores. Although occurrences of GI mucormycosis in immunocompetent hosts are uncommon, the mortality rate from GI mucormycosis can reach up to 85% [73] . GI involvement is found in about 8% of the patients. The stomach and colon are the most frequently affected organs in the GI system.

Fever, nausea, GI bleeding, perforation, abdominal pain are all signs of GI mucormycosis.

Establishing a correct diagnosis is challenging because of the non-specific clinical signs/symptoms that may or may not lead to suspicion of mucormycosis.

Endoscopically, stomach mucormycosis appears as a big ulcer with necrosis, ultimately presenting with an adherent, thick, green exudate [101, 102] . Surgical debridement of affected J o u r n a l P r e -p r o o f tissues and antifungal medication are used in treatment. The prescription of choice for the first treatment is intravenous amphotericin B (AmB) [103, 104] . Despite early diagnosis and intensive combination surgical and medicinal treatment [73] . COVID-19 has been linked to immunological dysregulation [105] . COVID-19 patients may be at risk of acquiring invasive fungal infections such as invasive candidiasis, aspergillosis, and Pneumocystis jiroveci infection [79, 106] . GI mucormycosis is an uncommon illness that should be considered if a COVID-19 patient develops an unusual stomach ulcer. Clinical suspicion and early treatment are essential for disease eradication. As a result, in the presence of signs suggestive of mucormycosis, preemptive treatment should be explored. More research is needed to determine if these two diseases are linked.

Disseminated mucormycosis is an uncommon condition that often affects neutropenic individuals with hematologic malignancies, transplant recipients, immunocompromised individuals, and people using deferoxamine [107] . Invasive fungal infections (IFIs) in COVID-19 have a unique etiology. Due to changes in host signaling pathways, fungi may infect people in a high-inflammatory state just as they do in immunosuppressed individuals [108] . Disseminated mucormycosis accounts for 9% of mucormycosis cases, and it has a high mortality rate. Renal involvement is common in disseminated illness [109] . The disease manifests with nonspecific clinical signs and is typically identified at autopsy. In the postmortem of a young man hospitalized with an acute anterior cerebral artery area infarction, an episode of disseminated mucormycosis in an immunocompetent host with COVID-19 infection was found. Following an autopsy, the cause of death was determined to be multiorgan failure due to disseminated mucormycosis caused by SARS-CoV-2 infection.

Steatohepatitis, hypothyroidism, thrombo-embolic illness, and a high BMI were all contributing factors [110] . Clinicians dealing with COVID-19 patients have a unique challenge owing to the lack of sensitive non-invasive modalities and biomarkers for J o u r n a l P r e -p r o o f identifying mucormycosis and the high mortality rate in untreated cases. The main comorbid predisposing characteristics are uncontrolled diabetes mellitus and systemic steroid usage [111] . The reported death rate for disseminated mucormycosis is between 68 and 96%, depending on several conditions, including host immunosuppression, early diagnosis, AmB treatment, and surgical debridement [69, 77, 112, 113] . The clinical and radiological symptoms of pulmonary and disseminated mucormycosis are non-specific and may coincide with attributes associated with COVID-19, making CAM diagnosis difficult [112] . Coronavirus infection with mucormycosis exhibits a high mortality rate due to complications such as cavernous sinus thrombosis, disseminated infection, and osteomyelitis. Diagnosis of J o u r n a l P r e -p r o o f mucormycosis is involved routine blood check-ups, biopsy, and radio imaging. The standard treatment for mucormycosis is first to reduce risk factors, remove the damaged tissue or organ by surgical procedure, and use intravenous antifungal drugs such as liposomal AmB [114, 115] .

Nearly any position of the human body can have an infection by the Mucorales. Earlier reports have indicated mucormycosis in kidneys [116] , bones [117, 118] , trachea [119, 120] , peritoneum [88, 121] , external otitis [122] , and superior vena cava syndrome [81] . Lymphopenia or lymphocytopenia is an illness with abnormally low counts of lymphocytes in the blood. It has recently been reported that severely ill patients infected with SARS-CoV-2 possess reduced lymphocytes levels [123, 124] . The patients who succumbed to COVID-19 exhibited lower lymphocytes than survivors [125] . Zheng has shown sufficiently reduced levels of CD8 + and CD4 + T cells [127] . Since lymphocytes play a crucial role in maintaining immune homeostasis, SARS-CoV-2 infected patients are more likely to have co-infection [128] . Usually, SARS-CoV-2 attacks lung tissue and J o u r n a l P r e -p r o o f alveolar interstitial lesions. In these conditions, patients are prone to invasive fungal infections, particularly those that enter through the pulmonary system.

The fungus, ubiquitously found in the atmosphere, enters immunocompromised host cells, produces fungal-specific T cells, and generates IL-4, IL-10, IL-17, and IFN-γ. The proinflammatory cytokines stimulate CD4 + T cells and further impair the host cell [129, 130] .

The hyphae of fungi interfere in the release of numerous immunomodulatory molecules such as RANTES (regulated upon activation, normal T cell expressed and secreted) and IFN-γ, secreted by NK cells and appear in the early phase of infection [131, 132] .

In IL-17, and IFN-γ [130] . Thus, there is a strong assertion that lymphopenia may increase the chance of developing mucormycosis.

Raised iron, glucose, and ketone bodies in the COVID-19 patient significantly induce host cell receptor GRP78 (glucose-regulated protein, 78 kDa) and spore coat protein, CotH3 [133, 134] . The ligands of fungus identify host receptors distinctive to particular cell types, for reported [137] . The genomic study supports the idea that Mucorales secrete secondary metabolites such as polyketide synthases, L-tryptophan dimethylallyl transferases, and nonribosomal peptide synthetases and indirectly affect the signaling mechanism [138] . These secondary metabolites directly affect the signaling mechanism between the host and fungal pathogens and facilitate the spreading of mucormycosis in the COVID-19 patients.

As mentioned above, misidentification and misdiagnosis of mucormycosis are one of the leading causes related to the high mortality rates of this infection. Therefore, it is vital to identify the fungal agents causing the infections. The gold standard for clinically identifying mucormycosis in the lab is based on the principle of Smith and Krichner criteria [139] . The essential criteria for microbiological identification are (i) black necrotic turbinate's easily, mistaken for dried crusted blood, (ii) blood-tinged nasal discharge with facial pain, (iii) soft peri-orbital, peri-nasal swelling plus discoloration and induration, (iv) ptosis of the eyelid, proptosis of the eyeball and complete ophthalmoplegia, and (v) numerous cranial nerve palsies.

Mycological identification of mucormycosis is based on the diameter of hyphae, the occurrence of septa, pigmentation, and the branching angle, so distinguishing this from other fungal infections.

The foundation for diagnosis of fungal infection relies on a few basic diagnostic techniques such as direct microscopy, fungal culture, histopathology, susceptibility testing, antigen testing, antibody testing, and molecular tests (DNA and RNA) of the specimen of the suspected specimen patient. In the next section, we briefly discuss the microbiological and pathological tests carried out regularly in labs to determine the fungal infection [140] .

This rapid test is commonly applied for superficial fungal infection and routinely performed in microbiological or pathological labs [141, 142] . (ii) Place the cover glass slip on the top of the slide and gently press to remove any air bubble. Wipe off excess solution with non-sticky tissue paper.

(iii) Now microscopic slide is ready for examination under the microscope. Low power magnification (10X) is utilized to visualize epithelial cells.

(iv) Fungal structure (hyphae or yeast) can also be examined at 10X magnification if any suspicious specimen is seen, then high magnification (40X) to ascertain other budding fungi. (iv) Observe the slide under UV light at low magnification (100X) and then higher magnification (400X).

A fungal culture test is a primary technique to confirm and diagnose fungal infection. Growing culture in culture medium takes several weeks.

(i) Culture medium is prepared to grow specimen.

(ii) Sample is placed onto Sabouraud's dextrose agar containing cycloheximide and chloramphenicol.

(iii) Samples containing nutrient media are incubated at a particular temperature over in an incubator and closely monitored during the experiment.

Following the identification of fungal species in the fungal culture, a susceptibility test is performed to determine the most suitable antifungal agents of the pathogenic microorganisms. The standard disk-diffusion method is exploited to test nondermatophyte filamentous fungi isolated from the fungal culture previously [146] .

(i) Mueller-Hinton agar (pH, 7.2-7.4) placed onto agar plates for optimal growth of molds at 24-48 hr [147] .

(ii) Agar plates should be streaked in three different directions after drying. The qualitative immunodiffusion test reveals the diagnosis of coccidioidomycosis by displaying coccidioidal IgM or IgG. In the diagnosis of acute primary coccidioidomycosis, the presence of IgM is beneficial [148] . IgG antibodies are produced in chronic infection and are typically detected by complement fixation assay [140] . 

The treatment approaches to counter mucormycosis are primarily based on novel methods.

The introduction of statins into CAM therapy has recently been proposed due to the potential The successful management of mucormycosis is based on four basic steps, namely (i) immediate diagnosis, (ii) urgent start of antifungal medication, (iii) adjunct therapy, (iv) reversal of essential predisposing factors, and (v) surgical intervention, if needed [162] .

Ascertaining an early diagnosis of mucormycosis is the mainstay for facilitating and initiating the start of antifungal therapy [163] .

The diagnosis of mucormycosis relies upon the identification of fungal species grown on laboratory culture media for mucormycosis and subsequent confirmation from histopathology [85] . The major disadvantage associated with culture identification is that most of the time, culture yields no growth. In that scenario, clinicians must utilize appropriate invasive testing to establish an early diagnosis. Physical examination of the patient's nostril airways and other signs and symptoms are necessary to diagnose mucormycosis.

With the advent of PCR, molecular diagnosis of mucormycosis has gained tremendously, exploiting 18S rDNA [164] . Recently, Gholinejad-Ghadi et al. amplified 18S rDNA regions using endpoint detection to identify mucormycetes [165] . Several articles report DNA sequencing of either internal transcribed spacer region of 18S rDNA regions to establish mucormycosis diagnosis [166] . PCR-based assay effectively detects circulating DNA and assist in molecular detection of pulmonary mucormycosis.

In the patient with ROCM, computed tomography (CT) scans usually discover sinusitis and cannot scan deeper tissues. A CT scan is routinely performed for early detection of pulmonary mucormycosis. A CT scan can differentiate pulmonary mucormycosis from aspergillosis based on sinusitis and numerous nodules (more than 10) in the scan. A more powerful magnetic resonance imaging technique detects infection in the orbital and central nervous systems. 

The patient undergoing immunosuppressive medication, mainly steroids, and corticosteroids, should be carefully monitored and checked every 12 hours. In the follow-up process, biochemical parameters are checked, and if no sign of improvement is recorded, then immediately all immunosuppressive medications are stopped. Restoring glucose levels is critical to balance normal acid-base status in a patient with a history of DKA.

The use of immunosuppressants, especially corticosteroids, should be minimized or stopped if possible. The immunosuppressant has been extensively used to reduce hospital stay and reduce the mortality of CAM patients (Moorthy A et al., 2021) [33] . Furthermore, to reduce the severity of infection caused by mucormycosis, the administration of iron, blood transfusion, and desferrioxamine should be carefully regulated. 

All authors declare no conflict of interest

Not applicable patients. The molecular mechanism involves the inhalation of spores reaching the alveoli of the lungs. Spores interact with alpha-beta integrins through ligands. The following molecular events trigger activation of EFGR, cell invasion, and finally, infection in the lungs.

Characterization of Bacterial and Fungal Infections in Hospitalized Patients With Coronavirus Disease 2019 and Factors Associated With Health Care-Associated Infections

A systematic review on SARS-CoV-2-associated fungal coinfections

COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions

An opportunistic pathogen during COVID-19

Diabetic Ketoacidosis in COVID-19: Unique Concerns and Considerations

COVID-19) Dashboard n

Expert Review of Anti-infective Therapy COVID-19 : fighting the invisible enemy with microRNAs ABSTRACT

Promiscuous Biological Features of Newly Emerged SARS-CoV-2 Facilitate its Unrestrained Outbreak: An Update

COVID-19 and SARS-CoV-2 Variants: Current Challenges and Health Concern

Coronavirus biology and replication: implications for SARS-CoV-2

Implications of SARS-CoV-2 Mutations for Genomic RNA Structure and Host microRNA Targeting

Epidemiology and Pathophysiology of COVID-19-Associated Mucormycosis: India Versus the Rest of the World

COVID-19-associated mucormycosis: An updated systematic review of literature

COVID-19-associated mucormycosis: Evidence-based critical review of an emerging infection burden during the pandemic's second wave in India

Global Prevalence of COVID-19-Associated Mucormycosis (CAM): Living Systematic Review and Meta-Analysis

Novel risk factors for Coronavirus disease-associated mucormycosis (CAM): a case control study during the outbreak in India. Epidemiology

COVID-19 and diabetes mellitus: from pathophysiology to clinical management

Mycosis mucorina: Ein Beitrag zur Kenntniss der menschlichen Fadenpilzerkrankungen

Mucormycosis; a new disease

The ecology of the Zygomycetes and its impact on environmental exposure

Epidemiology and Diagnosis of Mucormycosis: An Update

Mucormycosis: Battle with the Deadly Enemy over a Five-Year Period in India

Global Epidemiology of Mucormycosis

AS9e-final-web

COVID-19-associated mucormycosis: Case report and systematic review

Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India

The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports

Rhino-Orbital Mucormycosis Associated With COVID-19

Coronavirus Disease (Covid-19) Associated Mucormycosis (CAM): Case Report and Systematic Review of Literature

Sino-orbital mucormycosis in a COVID-19 patient: A case report

Title of the Article: Paranasal Mucormycosis in COVID-19 Patient

COVID-19 triggering mucormycosis in a susceptible patient: a new phenomenon in the developing world?

Mucor in a Viral Land: A Tale of Two Pathogens

COVID-19 and orbital mucormycosis

A case series of invasive mucormycosis in patients with COVID-19 infection

Mucormycosis coinfection associated with global COVID-19: a case series from India

SARS-CoV-2, Uncontrolled Diabetes and Corticosteroids-An Unholy Trinity in Invasive Fungal Infections of the Maxillofacial Region? A Retrospective, Multi-centric Analysis

Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum

Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbitalcerebral mucormycosis in 2826 patients in India -Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC)

Multicenter Epidemiologic Study of Coronavirus Disease-Associated Mucormycosis

Rare case of gastrointestinal mucormycosis with colonic perforation in an immunocompetent patient with COVID-19

COVID-19-associated rhino-orbital mucormycosis: a single-centre experience of 10 cases

Mucormycosis of Paranasal Sinuses of Odontogenic Origin Post COVID19 Infection: A Case Series

Post-COVID-19 Gastrointestinal Invasive Mucormycosis

Rhino-orbital mucormycosis in a COVID-19 patient

CT and MRI Findings of Invasive Mucormycosis in the Setting of COVID-19: Experience From a Single Center in India

Orbital infarction syndrome secondary to rhino-orbital mucormycosis in a case of COVID-19: Clinico-radiological features

Rise of the phoenix: Mucormycosis in COVID-19 times

Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study

Secondary infection with rhino-orbital cerebral mucormycosis associated with COVID-19

Mucormycosis with orbital compartment syndrome in a patient with COVID-19

Bronchopleural fistula development in the setting of novel therapies for acute respiratory distress syndrome in SARS-CoV-2 pneumonia

Acute Invasive Rhino-Orbital Mucormycosis in a Patient With COVID-19-Associated Acute Respiratory Distress Syndrome

Rhinocerebral Mucormycosis and COVID-19 Pneumonia

Pulmonary aspergillosis and mucormycosis in a patient with COVID-19

A Fatal Case of Rhizopus azygosporus Pneumonia Following COVID-19

Mucormycosis after Coronavirus disease 2019 infection in a heart transplant recipient -Case report and review of literature

Rare and Fatal Gastrointestinal Mucormycosis (Zygomycosis) in a COVID-19 Patient: A Case Report

A challenging complication following SARS-CoV-2 infection: a case of pulmonary mucormycosis

Mixed mold infection with Aspergillus fumigatus and Rhizopus microsporus in a severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) patient

Fulminant mucormycosis complicating coronavirus disease 2019 (COVID-19)

Rhinoorbital mucormycosis during steroid therapy in COVID-19 patients: A case report

Mucormycosis in patients with COVID-19: A cross-sectional descriptive multicentre study from Iran

Severe rhinocerebral mucormycosis case developed after COVID 19

A Case of Fatal Rhino-Orbital Mucormycosis Associated With New Onset Diabetic Ketoacidosis and COVID-19

Autopsy Proven Pulmonary Mucormycosis Due to Rhizopus microsporus in a Critically Ill COVID-19 Patient with Underlying Hematological Malignancy

The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports

Mucormycosis, a threatening opportunistic mycotic infection

Challenges in the diagnosis and treatment of mucormycosis

Fungal Infections of Oral Cavity : Diagnosis , Management , and Association with COVID

Epidemiology and outcome of zygomycosis: a review of 929 reported cases

Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment

Rhinocerebral mucormycosis: pathways of spread

Imaging features of rhinocerebral mucormycosis: A study of 43 patients

Epidemiology and clinical manifestations of mucormycosis

When Uncontrolled Diabetes Mellitus and Severe COVID-19 Converge : The Perfect Storm for Mucormycosis

COVID-19 associated pulmonary aspergillosis

An unusual presentation of opportunistic mucormycosis

Pulmonary Mucormycosis Over 130 Years: A Case Report and Literature Review

Chronic pulmonary mucormycosis: an emerging fungal infection in diabetes mellitus

Histopathologic diagnosis of fungal infections in the 21st century

COVID-19-Associated Mucormycosis (CAM): An Updated Evidence Mapping

COVID-19 and mucormycosis superinfection: the perfect storm

Mucormycosis: emerging prominence of cutaneous infections

Cutaneous mucormycosis

Cutaneous mucormycosis

Wound infection due to Absidia corymbifera and Candida albicans with fatal outcome

Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between

Cutaneous zygomycosis

Primary cutaneous mucormycosis in an immunocompetent host

Nosocomial post-traumatic cutaneous mucormycosis: a systematic review

Ecthymalike lesions on the leg of an immunocompromised patient. Primary cutaneous mucormycosis

Disseminated zygomycosis heralded by a subtle cutaneous finding

Diagnosis of invasive aspergillosis and mucormycosis in immunocompromised patients by seminested PCR assay of tissue samples

Development of a single tube multiplex real-time PCR to detect the most clinically relevant Mucormycetes species

Fatal invasive gastric mucormycosis occurring with emphysematous gastritis: case report and literature review

Gastrointestinal Manifestations and Associated Health Outcomes of COVID-19: A Brazilian Experience From the Largest South American Public Hospital

Recent advances in the management of mucormycosis: from bench to bedside

Super aggregated form of Amphotericin B: a novel way to increase its therapeutic index

T cell responses in patients with COVID-19

Fungal Co-infections Associated with Global COVID-19 Pandemic: A Clinical and Diagnostic Perspective from China

Two cases of disseminated mucormycosis in patients with hematological malignancies and literature review

DAMP signaling in fungal infections and diseases

Disseminated mucormycosis with renal involvement

Autoptic identification of disseminated mucormycosis in a young male presenting with cerebrovascular event, multi-organ dysfunction and COVID-19 infection

The Emergence of COVID-19 Associated Mucormycosis: Analysis of Cases From 18 Countries

Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium

COVID-19 associated mucormycosis: the urgent need to reconsider the indiscriminate use of immunosuppressive drugs

Associated Fungal Infections, Related to the Global Covid-19 Pandemic (Literature Review)

Defining and managing COVID-19

ECMM/ISHAM consensus criteria for research and clinical guidance

Successful treatment of primary bilateral renal mucormycosis with bilateral nephrectomy

Osteomyelitis secondary to cutaneous mucormycosis

Saksenaea vasiformis osteomyelitis

Tracheal mucormycosis

Tracheal mucormycosis presented as an intraluminal soft tissue mass

Successful treatment of mucormycosis peritonitis with liposomal amphotericin B in a patient on long-term peritoneal dialysis

Fungal air spora at Ibadan, Nigeria

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

Functional exhaustion of antiviral lymphocytes in COVID-19 patients

Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)

Genomic and protein structure modelling analysis depicts the origin and pathogenicity of 2019-nCoV

A New Method for Reactivating and Expanding T Cells Specific for Rhizopus oryzae

Mucoralesspecific T cells emerge in the course of invasive mucormycosis and may be used as a surrogate diagnostic marker in high-risk patients

Rhizopus oryzae hyphae are damaged by human natural killer (NK) cells, but suppress NK cell mediated immunity

Natural killer cellmediated damage of clinical isolates of mucormycetes

The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice

CotH3 mediates fungal invasion of host cells during mucormycosis

Inhibition of EGFR Signaling Protects from Mucormycosis

GRP78 and Integrins Play Different Roles in Host Cell Invasion during Mucormycosis

Analysis of a foodborne fungal pathogen outbreak: virulence and genome of a Mucor circinelloides isolate from yogurt

Genetic and Metabolic Aspects of Primary and Secondary Metabolism of the Zygomycetes

Cerebral mucormycosis; a report of three cases

Fungal diagnostics

Comparison of diagnostic methods in the evaluation of onychomycosis

Microscopic potassium hydroxide preparation

Rapid detection of fungi in tissues using calcofluor white and fluorescence microscopy

Rapid diagnosis of Acanthamoeba keratitis using calcofluor white

Calcofluor White: A Review of its Uses and Applications in Clinical Mycology and Parasitology

Antifungal Susceptibility Testing of Filamentous Fungi

Epidemiologic, clinical, and diagnostic aspects of coccidioidomycosis

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

COVID-19 associated mucormycosis: evolving technologies for early and rapid diagnosis

Laboratory diagnosis of mucormycosis: current status and future perspectives

Phylogeny and PCR identification of clinically important Zygomycetes based on nuclear ribosomal-DNA sequence data

Quantitative PCR (qPCR) Detection of Mucorales DNA in Bronchoalveolar Lavage Fluid To Diagnose Pulmonary Mucormycosis

Synopsis on Pharmotechnological Approaches in Diagnostic to Management Strategies in Fighting Against COVID-19

Identifying Mucormycosis Severity in Indian COVID-19 Patients: A Nano-Based Diagnosis and the Necessity for Critical Therapeutic Intervention

Plasmonic gold nanoparticles for detection of fungi and human cutaneous fungal infections

Nanoemulsion as an Effective Treatment against Human-Pathogenic Fungi

Myconanotechnology: a new and emerging science

Mucormycosis and glucose-regulated protein 78 in COVID-19: Amenable to statin treatment?

Mycovia Pharmaceuticals Inc. A Phase 3, Randomized, Double-Blind

Oral Capsules in the Treatment of Subjects With Recurrent Vulvovaginal Candidiasis. clinicaltrials.gov

Open-Label Study to Evaluate the Safety and Efficacy of APX001 in the Treatment of Patients With Invasive Mold Infections Caused by Aspergillus Species or Rare Molds. clinicaltrials.gov

Novel perspectives on mucormycosis: pathophysiology, presentation, and management

Nanoparticle-Based Mycosis Vaccine

Molecular Strategies to Diagnose Mucormycosis

Identification of Mucorales in patients with proven invasive mucormycosis by polymerase chain reaction in tissue samples

Increasing incidence of mucormycosis in a large Spanish hospital from 2007 to 2015: Epidemiology and microbiological characterization of the isolates

Successful treatment of cutaneous zygomycosis with intravenous amphotericin B followed by oral posaconazole in a multivisceral transplant recipient

Successful treatment of a case with rhinoorbital-cerebral mucormycosis by the combination of neurosurgical intervention and the sequential use of amphotericin B and posaconazole

Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis

Should statins be considered for the management of mucormycosis in COVID-19?

Isavuconazole: a comprehensive review of spectrum of activity of a new triazole

In Vitro Activity of Isavuconazole and Comparators against Clinical Isolates of the Mucorales Order

Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis

Natural resistance, iron and infection: a challenge for clinical medicine

Immunomodulation of invasive fungal infections

Iron Chelation in Local Infection

Role of Iron Chelators in Mucormycosis

Rhinocerebral mucormycosis in Taiwan

Mucormycosis: ten-year experience at a tertiary-care center in Greece

Successful treatment of pulmonary mucormycosis in an allogenic bone-marrow transplant recipient with combined medical and surgical therapy

Zygomycosis in the 1990s in a tertiary-care cancer center

Mucormycosis-induced upper gastrointestinal ulcer perforation in immunocompetent patients: a report of two cases